Overview
No overview information available.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Research Report
LH-1801: A Comprehensive Monograph on a Novel SGLT2 Inhibitor for Diabetes Mellitus
Executive Summary
This report provides a comprehensive analysis of LH-1801, an investigational, orally administered small-molecule drug being developed for the treatment of diabetes mellitus. LH-1801 is classified as a sodium-glucose cotransporter 2 (SGLT2) inhibitor, a modern class of antidiabetic agents renowned for their cardiorenal protective benefits in addition to glycemic control. The drug is the product of a strategic collaboration between two prominent Chinese entities: the Shanghai Institute of Materia Medica, an affiliate of the Chinese Academy of Sciences, and Jiangsu Lianhuan Pharmaceutical Co., Ltd. This joint effort underscores a focused, domestic strategy to develop a novel therapeutic with independent intellectual property rights within China.
The development program for LH-1801 is currently at an advanced stage, with pivotal Phase 3 clinical trials underway in China for its primary indication, Type 2 Diabetes Mellitus (T2DM). A Phase 1 study for Type 1 Diabetes Mellitus (T1DM) has also been completed, indicating a potential expansion of its therapeutic scope. The core value proposition of LH-1801 is built upon two foundational pillars. First, extensive preclinical data from multiple animal models suggest that LH-1801 may possess superior hypoglycemic efficacy compared to dapagliflozin, a well-established, blockbuster SGLT2 inhibitor. This claim, if validated in human trials, could position LH-1801 as a best-in-class agent for glycemic management.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|
No clinical trials found
No clinical trials found for this drug
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| No Health Canada approvals found for this drug. | |||||
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.